Ask AI
ProCE Banner Activity

P052 (MK-8591A-052) Phase III Trial of Switch From BIC/FTC/TAF to Doravirine/Islatravir: Impact on Weight and Body Composition at Wk 48

Conference Coverage
Slideset

In the phase III P052 trial for people living with virologically suppressed HIV, switch to doravirine/islatravir had minimal impact on weight and body composition compared with continuing BIC/FTC/TAF through Week 48.

Released: October 23, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare